Achillion fourth quarter revenue is $2 million for three months ended December 31.

Except as expressly required by law, Actavisdisclaims any intent or obligation to upgrade or revise these forward-looking statements.. Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010 Achillion Pharmaceuticals, Inc. , a head in the discovery and development of small molecule drugs to combat the most complicated infectious diseases, reported financial outcomes for the three and a year finished December 31 today, 2010. December 31 For the three months ended, 2010, the business reported a net lack of $6.2 million, compared to a net lack of $6.december 31 7 million in the three months ended, 2009. December 31 For the entire year ended, 2010, the Company’s net loss was $25.5 million, in comparison to a net loss of $25.december 31 9 million for the year ended, 2009.2 million.All treatment groupings progressed as planned in the protocol. The locomotor-training groupings had significant improves in the duration of stepping time, decreases in the level of body-weight support and assistance required, and boosts in training swiftness over 36 classes .6 km per hour , and the minimum level of body-weight support was 11.9 percent. Individuals also progressed in the part of the training involving walking over ground . Participants in the home-exercise group also got improvement in all activities . The mean heart rate during the midpoint of each treadmill work out was 90 beats each and every minute in both locomotor-schooling groupings and 77 beats per minute in the home-exercise group .